Altaf, Ataf Ali et al. 2015. “A Review on the Medicinal Importance of Pyridine Derivatives.” Http://Www.Sciencepublishinggroup.Com 1(1):1.
Ashley, Noah T., Zachary M. Weil, and Randy J. Nelson. 2012. “Inflammation: Mechanisms, Costs, and Natural Variation.” Annual Review of Ecology, Evolution, and Systematics 43(1):385–406. Retrieved June 3, 2018 (http://www.annualreviews.org/doi/10.1146/annurev-ecolsys-040212-092530).
Burguete, Asunción et al. 2007. “Synthesis and Anti-Inflammatory/Antioxidant Activities of Some New Ring Substituted 3-Phenyl-1-(1,4-Di-N-Oxide Quinoxalin-2-Yl)-2-Propen-1-One Derivatives and of Their 4,5-Dihydro-(1H)-Pyrazole Analogues.” Bioorganic & Medicinal Chemistry Letters 17(23):6439–43.
Burguete, Asunción et al. 2011. “Synthesis and Biological Evaluation of New Quinoxaline Derivatives as Antioxidant and Anti-Inflammatory Agents.” Chemical Biology & Drug Design 77(4):255–67.
Crunkhorn, Sarah. 2012. “Deal Watch: Abbott Boosts Investment in NRF2 Activators for Reducing Oxidative Stress.” Nature Reviews Drug Discovery 2012 11:2.
Food and Drug Administration (FDA). 2016. “Guidance for Industry Safety Testing of Drug Metabolites Guidance for Industry.” Guidance Revision 1(November).
Franchi, Jocelyne et al. 2008. “Cell Model of Inflammation.” Bioscience Reports 28(1):23.
Le Goff, Géraldine and Jamal Ouazzani. 2014. “Natural Hydrazine-Containing Compounds: Biosynthesis, Isolation, Biological Activities and Synthesis.” Bioorganic and Medicinal Chemistry 22(23):6529–44.
Gold, Ralf et al. 2012. “Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis.” N Engl J Med 12367(20):1098–1107.
Hazeldine, Stuart T. et al. 2002. “II. Synthesis and Biological Evaluation of Some Bioisosteres and Congeners of the Antitumor Agent, 2-(4-[(7-Chloro-2-Quinoxalinyl)Oxy]Phenoxy)Propionic Acid (XK469).” Journal of Medicinal Chemistry 45(14):3130–37.
Hetrick, Evan M. and Mark H. Schoenfisch. 2009. “Analytical Chemistry of Nitric Oxide.” Annual Review of Analytical Chemistry 2(1):409–33. Retrieved May 15, 2018 (http://www.annualreviews.org/doi/10.1146/annurev-anchem-060908-155146).
Hu, Chenqi, Aimee L. Eggler, Andrew D. Mesecar, and Richard B. Van Breemen. 2011. “Modification of Keap1 Cysteine Residues by Sulforaphane.” Chemical Research in Toxicology 24(4):515–21.
Hu, Longqin et al. 2013. “Discovery of a Small-Molecule Inhibitor and Cellular Probe of Keap1-Nrf2 Protein-Protein Interaction.” Bioorganic and Medicinal Chemistry Letters 23(10):3039–43.
Jain, Atul D. et al. 2015. “Probing the Structural Requirements of Non-Electrophilic Naphthalene-Based Nrf2 Activators.” European Journal of Medicinal Chemistry 103:252–68.
Jaso, Andrés, Belén Zarranz, Ignacio Aldana, and Antonio Monge. 2005. “Synthesis of New Quinoxaline-2-Carboxylate 1,4-Dioxide Derivatives as Anti-Mycobacterium Tuberculosis Agents.” Journal of Medicinal Chemistry 48(6):2019–25.
Jiang, Zheng-Yu et al. 2014. “Discovery of Potent Keap1–Nrf2 Protein–Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis.” Journal of Medicinal Chemistry 57(6):2736–45.
Kajal, Anu, Suman Bala, Neha Sharma, Sunil Kamboj, and Vipin Saini. 2014. “Therapeutic Potential of Hydrazones as Anti-Inflammatory Agents.” International Journal of Medicinal Chemistry 2014(August 2016):761030.
Keum, Young-Sam, Woo-Sik Jeong, and A. N. Tony Kong. 2004. “Chemoprevention by Isothiocyanates and Their Underlying Molecular Signaling Mechanisms.” Mutation Research 555(555):191–202.
Kikuchi, Norihiro et al. 2010. “Nrf2 Protects against Pulmonary Fibrosis by Regulating the Lung Oxidant Level and Th1/Th2 Balance.”
Kumar, K. Shiva et al. 2012. “AlCl3induced (Hetero)Arylation of 2,3-Dichloroquinoxaline: A One-Pot Synthesis of Mono/Disubstituted Quinoxalines as Potential Antitubercular Agents.” Bioorganic and Medicinal Chemistry 20(5):1711–22.
Kwak, Mi Kyoung and Thomas W. Kensler. 2010. “Targeting NRF2 Signaling for Cancer Chemoprevention.” Toxicology and Applied Pharmacology 244(1):66–76.
Lanter, James, Xuqing Zhang, and Zhihua Sui. 2011. “Medicinal Chemistry Inspired Fragment-Based Drug Discovery.” Pp. 421–45 in Methods in enzymology, vol. 493. Retrieved February 13, 2019 (http://www.ncbi.nlm.nih.gov/pubmed/21371600).
Lee, Jeong Sang and Young Joon Surh. 2005. “Nrf2 as a Novel Molecular Target for Chemoprevention.” Cancer Letters 224(2):171–84.
Liu, Hua, Albena T. Dinkova-Kostova, and Paul Talalay. 2008. Coordinate Regulation of Enzyme Markers for Inflammation and for Protection against Oxidants and Electrophiles. Retrieved August 28, 2018 (www.pnas.org/cgi/content/full/).
Magesh, Sadagopan, Yu Chen, and Longqin Hu. 2012. “Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents.” Medicinal Research Reviews 32(4):687–726.
Marcotte, Douglas et al. 2013. “Small Molecules Inhibit the Interaction of Nrf2 and the Keap1 Kelch Domain through a Non-Covalent Mechanism.” Bioorganic and Medicinal Chemistry 21(14):4011–19.
Moody, Christopher J., Elizabeth Swann, Susan Houlbrook, Miriam a Stephens, and Ian J. Stratford. 2015. “Synthesis and Biological Activity of Quinoxaline Derivatives.” World Journal of Pharmaceutical Research 4(7):1892–1900.
Nakhi, Ali et al. 2012. “Pyrrolo[2,3-b]Quinoxalines as Inhibitors of Firefly Luciferase: Their Cu-Mediated Synthesis and Evaluation as False Positives in a Reporter Gene Assay.” Bioorganic and Medicinal Chemistry Letters 22(20):6433–41.
Narang, R., B. Narasimhan, and S. Sharma. 2012. “A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives.” Current Medicinal Chemistry 19(4):569–612.
Patidar, Ashutosh Kumar, M. Jeyakandan, Ashok Kumar Mobiya, and G. Selvam. 2011. “Exploring Potential of Quinoxaline Moiety.” International Journal of PharmTech Research 3(1):386–92.
Pereira, Joana A. et al. 2015. “Quinoxaline, Its Derivatives and Applications: A State of the Art Review.” European Journal of Medicinal Chemistry 97:664–72. Retrieved December 11, 2017 (http://www.ncbi.nlm.nih.gov/pubmed/25011559).
Raghavendra Rao, K. et al. 2015. “Biological Activity of Drug like Small Molecules Based on Quinoxaline Containing Amino Substitution at C-2.” Der Pharma Chemica 7(2):77–85.
Rollas, Sevim and Ş. Güniz Küçükgüzel. 2007. “Biological Activities of Hydrazone Derivatives.” Molecules 12(8):1910–39.
Rong, Frank et al. 2007. “Structure–activity Relationship (SAR) Studies of Quinoxalines as Novel HCV NS5B RNA-Dependent RNA Polymerase Inhibitors.” Bioorganic & Medicinal Chemistry Letters 17(6):1663–66.
Smits, Rogier A. et al. 2008. “Fragment Based Design of New H 4 Receptor−Ligands with Anti-Inflammatory Properties in Vivo.” Journal of Medicinal Chemistry 51(8):2457–67.
Tafazoli, Shahrzad, Mariam Mashregi, and Peter J. O’Brien. 2008. “Role of Hydrazine in Isoniazid-Induced Hepatotoxicity in a Hepatocyte Inflammation Model.” Toxicology and Applied Pharmacology 229(1):94–101. Retrieved February 13, 2019 (http://www.ncbi.nlm.nih.gov/pubmed/18295292).
Tariq, Sana, K. Somakala, and Mohd. Amir. 2018. “Quinoxaline: An Insight into the Recent Pharmacological Advances.” European Journal of Medicinal Chemistry 143:542–57. Retrieved February 13, 2019 (https://www.sciencedirect.com/science/article/pii/S0223523417309674?via%3Dihub).
Wallace, John L. 2005. “Nitric Oxide as a Regulator of Inflammatory Processes.” Memórias Do Instituto Oswaldo Cruz 100(suppl 1):5–9. Retrieved March 16, 2019 (http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762005000900002&lng=en&tlng=en).
Wilson, Anthony J., Jeffrey K. Kerns, James F. Callahan, and Christopher J. Moody. 2013. “Keap Calm, and Carry on Covalently.” Journal of Medicinal Chemistry 56(19):7463–76.
Winkel, Angelika F. et al. 2015. “Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling.” Journal of Biological Chemistry 290(47):28446–55.
Wu, Kui et al. 2012. “Multisubstituted Quinoxalines and Pyrido[2,3-d]Pyrimidines: Synthesis and SAR Study as Tyrosine Kinase c-Met Inhibitors.” Bioorganic and Medicinal Chemistry Letters 22(20):6368–72.
Yang, Li, Dushani L. Palliyaguru, and Thomas W. Kensler. 2016. “Frugal Chemoprevention: Targeting Nrf2 with Foods Rich in Sulforaphane.” Seminars in Oncology 43(1):146–53.
de Zeeuw, Dick et al. 2013. “Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease.” New England Journal of Medicine 369(26):2492–2503.
Zhao, Cui Rong, Zu Hua Gao, and Xian Jun Qu. 2010. “Nrf2-ARE Signaling Pathway and Natural Products for Cancer Chemoprevention.” Cancer Epidemiology 34(5):523–33.